IL17A and myeloid sarcoma: In addition, the downregulating of miR-155-5p targeting with IL17 can be confirmed in EAE.[41] Decreased immune system activation and downregulation of miR-155-5p in progressive MS may be the result of raised SOCS6 expressions in SPMS CD4+ T cells.[40] These results highlighted the importance of miR-155-5p in MS.